Navigation Links
ASEAN News: Epeius Biotechnologies Gains Commercial Approval for Rexin-G(R), a Tumor-Targeted Gene-Based Medicine for Metastatic Cancer
Date:12/18/2007

bedside."

Now that Rexin-G is commercially available to Philippine physicians and their patients, and to a host of medical tourists from the United States, Europe, and Japan, the next step is to expand its availability to these countries and to ASEAN countries that share cooperative affiliations with the Philippines. Epeius Biotechnologies has intensified its efforts to gain product registration in the United States-following several years of safety studies in the USA, Epeius has formally opened three advanced Phase I/II trials in San Marino and Santa Monica, California, for chemo-resistant pancreatic cancer, breast cancer, and sarcoma. Based again on unprecedented single-agent efficacy and over-all safety, the US FDA recently approved a Phase II Registration Protocol for osteosarcoma which includes participation of children and adolescents. For additional information about ongoing clinical trials in the United States, contact our Medical Director, Dr. Erlinda M. Gordon at egordon@epeiusbiotech.com.

About Epeius Biotechnologies

Epeius Biotechnologies Corporation is a privately held biopharmaceutical company dedicated to the advancement of genetic medicine with the development and commercialization of its lead products and proprietary targeted delivery systems. Credited with innovations ranging from gene discovery, to designer therapeutic genes, to pathotropic (disease-seeking) targeting, to ultra high-performance vector engineering, to advanced biopharmaceutical manufacturing and bioprocess development, Epeius Biotechnologies is well positioned to 'launch' its enabling platform technologies for the benefit of cancer patients worldwide. Meanwhile, rapid advances in clinical drug development provide Epeius with a unique opportunity for early revenues from the sale of its lead product to the Philippines and reciprocating ASEAN countries -- thus demonstrating the high growth potential of a small biotec
'/>"/>

SOURCE Epeius Biotechnologies Corporation
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Vical Begins Phase 1 Trial of DNA Vaccine Against H5N1 Pandemic Influenza
2. Oritavancin Demonstrates Superior In Vitro Activity to Vancomycin and Metronidazole Against C. Difficile Bacteria
3. Oritavancin Demonstrates Potent and Rapid In Vitro Activity Against MRSA, VRE and Other Strains of Resistant Bacteria
4. Molnlycke Drives Home the Fight Against Staph and Other MRSA Infections
5. Mayo Clinic Study Finds FDA Warning Against Anti-Nausea Drug Droperidol Unnecessary
6. Targeted Nanoparticles Offer Promise in the Battle Against Cancer
7. Interim Safety Data Favorable for Vicals Phase 2 Trial of DNA Vaccine Against CMV
8. Roche Announces Positive Results in Solid Tumors Using Human Monoclonal Antibody Against IGF-1R (R1507)
9. Jennerex Presents Clinical Data From JX-594 Demonstrating Tumor Efficacy Against Advanced Liver Cancers
10. Semafores PI3 Kinase Inhibitor SF1126 is Active Against Tumor and Tumor Cells and Synergizes with Standard Chemotherapy Agents
11. BD and PEPFAR Collaborate to Strengthen Laboratory Systems in Fight Against HIV/AIDS and TB
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/31/2015)... 31, 2015 Pepperl+Fuchs, a world leader ... Corporation, a leading provider of HART protocol devices. ... further extend its integrated solutions offerings and strengthen ... "We are pleased to add the MACTek ... Jim Bolin , Pepperl+Fuchs, executive vice president ...
(Date:8/31/2015)... Diagnostics today announced a collaboration with Merck, known as MSD ... Canada , to develop Daktari,s rapid hepatitis C ... million over the next 3.5 years, will support an accelerated ... Daktari,s HCV test. The Daktari technology forms ... levels of virus directly in a single drop of blood ...
(Date:8/31/2015)... Aug. 31, 2015  On August 5, 2015, the ... Oregon denied motions to dismiss securities class ... ) and certain of its directors. The class actions ... and dump" scheme to artificially inflate Galena,s stock price, ... stock price was inflated, sold massive amounts of their ...
Breaking Medicine Technology:Daktari Enters Collaboration Agreement with Merck to Develop Test for Hepatitis C Virus 2Daktari Enters Collaboration Agreement with Merck to Develop Test for Hepatitis C Virus 3Galena Biopharma, Inc. Stock Alert: Schubert Firm Investigates Potential Breaches of Fiduciary Duty 2
... May 15, 2012  Boston Scientific Corporation (NYSE: ... trial, which evaluated the acute safety of the Lotus™ ... disease.  The Lotus Aortic Valve System is the first ... that is designed to minimize aortic regurgitation (leaking) and ...
... year,s Annual Scientific Meeting of the American Pain ... will present results from clinical studies utilizing a ... is designed to be crush-resistant and to protect ... to prescription opioid drugs is considered an efficient ...
Cached Medicine Technology:Boston Scientific Announces Positive Data From Lotus™ Transcatheter Aortic Valve Trial 2Boston Scientific Announces Positive Data From Lotus™ Transcatheter Aortic Valve Trial 3Boston Scientific Announces Positive Data From Lotus™ Transcatheter Aortic Valve Trial 4Boston Scientific Announces Positive Data From Lotus™ Transcatheter Aortic Valve Trial 5INTAC™ Technology Combats Misuse of Extended Release Drugs 2
(Date:8/31/2015)... ... 31, 2015 , ... Diablo Publications (DP), a ... has officially launched a new website and company identity ( diablopublications.com) . According ... closely aligned with the company’s strategic vision for growth and expansion over the ...
(Date:8/31/2015)... (PRWEB) , ... August 31, 2015 , ... ... AdvantaClean franchise business with a ribbon-cutting ceremony on Aug. 26, generously hosted by ... and booking inspection appointments via AdvantaClean’s National Call Center and website since Aug. ...
(Date:8/31/2015)... NJ (PRWEB) , ... August 31, 2015 , ... ... and provider of the CME-certified annual Chemotherapy Foundation Symposium: Innovative Cancer Therapy ... to be held Nov. 4 – 6 in New York City. The annual ...
(Date:8/31/2015)... , ... August 31, 2015 , ... ... peers may be at a greater risk for injury, potentially because they are ... University of Pittsburgh Graduate School of Public Health analysis discovered. , The ...
(Date:8/31/2015)... ... 2015 , ... On Saturday, May 30th, 2015, Best Drug Rehabilitation sponsored a ... Mendon, IL. The purpose behind this concert was to raise money for music education ... Drug Rehabilitation’s sponsorship of “Music with a Mission” helped with a portion of the ...
Breaking Medicine News(10 mins):Health News:Diablo Publications Launches New Company Website 2Health News:Diablo Publications Launches New Company Website 3Health News:Ribbon Cutting Launches AdvantaClean of Madison County 2Health News:Physicians’ Education Resource® Seeks Abstracts for the Upcoming Chemotherapy Foundation Symposium: Innovative Cancer Therapy for Tomorrow® 2Health News:Physicians’ Education Resource® Seeks Abstracts for the Upcoming Chemotherapy Foundation Symposium: Innovative Cancer Therapy for Tomorrow® 3Health News:Physicians’ Education Resource® Seeks Abstracts for the Upcoming Chemotherapy Foundation Symposium: Innovative Cancer Therapy for Tomorrow® 4Health News:Television Viewing Linked to Higher Injury Risk in Hostile People 2Health News:Television Viewing Linked to Higher Injury Risk in Hostile People 3Health News:2015 "Music With A Mission" Sponsor Best Drug Rehabilitation Releases Artist Compilation Video 2Health News:2015 "Music With A Mission" Sponsor Best Drug Rehabilitation Releases Artist Compilation Video 3
... Improved Benefits for Prevention, Mental,Health and Low-Income ... Pa., June 12 SUMMARY: Today a,minority ... to protect and,improve Medicare for the 44 ... Improvements for Patients and Providers Act, which ...
... by Senate Vote to Block Medicare Improvement Bill, ... Prevention, Mental,Health and Low-Income Programs, Boosted Quality through ... was issued,today by AARP Maryland:, SUMMARY: Today ... to protect and improve Medicare for the 44 ...
... on food safety , , THURSDAY, June 12 (HealthDay News) ... outbreak of salmonella-contaminated tomatoes has risen to 228 in ... Thursday. , Also Thursday, Congressional investigators said the U.S. ... own stated goals of protecting the nation,s food supply. ...
... physicians to more accurately diagnose and treat heart ... to Syntermed, an Atlanta-based nuclear medicine imaging and ... analysis (MHPA), a technology developed by Emory medical ... , MHPA is designed to quickly and reliably ...
... Facilities Provide a Unique Market ... ... today,that it has been awarded a coveted Federal Supply Contract (Contract ... the company to market and sell the LifeBed(TM) Patient Vigilance,System to ...
... head trauma deaths since law revoked in 2003 , , ... years after Pennsylvania repealed its universal motorcycle helmet law, ... injury deaths and a 42 percent increase in head ... The state,s universal helmet law was repealed in 2003. ...
Cached Medicine News:Health News:AARP PENNSYLVANIA NEWS ALERT: AARP Dismayed by Senate Vote to Block Medicare Improvement Bill 2Health News:AARP PENNSYLVANIA NEWS ALERT: AARP Dismayed by Senate Vote to Block Medicare Improvement Bill 3Health News:AARP Maryland Key Vote News Alert 2Health News:AARP Maryland Key Vote News Alert 3Health News:228 People in 22 States Sickened in Ongoing Salmonella-Tomato Outbreak 2Health News:228 People in 22 States Sickened in Ongoing Salmonella-Tomato Outbreak 3Health News:228 People in 22 States Sickened in Ongoing Salmonella-Tomato Outbreak 4Health News:228 People in 22 States Sickened in Ongoing Salmonella-Tomato Outbreak 5Health News:Syntermed licenses Emory imaging technology for improved evaluation of heart failure patients 2Health News:Hoana Medical, Inc. Awarded a Federal Supply Contract Through the U.S. Department of Veteran Affairs 2Health News:Pennsylvania Injuries Rise After Repeal of Helmet Law 2
The proximally modular S-ROM Total Hip System provides custom capability at non-custom prices and is competitive with conventional porous coated systems....
The proximally modular S-ROM Total Hip System provides custom capability at non-custom prices and is competitive with conventional porous coated systems....
Exactech's AcuMatch C-Series (Cemented Femoral Stem) is designed to provide solutions to the problems which compromise both the short and long term successful outcome of cemented hip arthroplasty....
Exactech's AcuMatch C-Series (Cemented Femoral Stem) is designed to provide solutions to the problems which compromise both the short and long term successful outcome of cemented hip arthroplasty....
Medicine Products: